A Phase 1/2A Dose Escalation Study of 2-hydroxyoleic Acid (2-OHOA; Minerval) in Adult Patients With Advanced Solid Tumours Including Malignant Glioma

Trial Profile

A Phase 1/2A Dose Escalation Study of 2-hydroxyoleic Acid (2-OHOA; Minerval) in Adult Patients With Advanced Solid Tumours Including Malignant Glioma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 05 Jun 2017

At a glance

  • Drugs 2-hydroxyoleic acid (Primary)
  • Indications Glioma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Lipopharma
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 05 Jun 2017 Final results published in a Lipopharma media release.
    • 02 Jun 2017 Final results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top